The effect of a smoking cessation program on women with gynecologic cancer

Robinson, William R.; Regn, R.; Shamsnia, Lily

doi:10.1016/j.ygyno.2015.07.030

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent prospective study among participants from the Cancer Prevention Study-II Nutrition Cohort reported high rates of quitting behavior among smokers with cancer in the 2-4 years following a cancer diagnosis [14]. Patient, physician and system level factors impede the delivery of effective tobacco cessation programs during cancer care [35, 42-44]. Only half of NCI-designated comprehensive cancer centers, in 2009, had any type of tobacco treatment program [45].…”

Section: Introductionmentioning

confidence: 99%

Integrating tobacco treatment into cancer care: Study protocol for a randomized controlled comparative effectiveness trial

Park

Ostroff

Perez

et al. 2016

Contemporary Clinical Trials

View full text Add to dashboard Cite

Background Despite the well-established risks of persistent smoking, 10-30% of cancer patients continue to smoke after diagnosis. Evidence based tobacco treatment has yet to be integrated into routine oncology care. This paper describes the protocol, manualized treatment, evaluation plan, and overall study design of comparing the effectiveness and cost of two treatments across two major cancer centers. Methods/Design A two-arm, two-site randomized controlled comparative effectiveness trial is testing the hypothesis that an Intensive Treatment (IT) intervention is more effective than a Standard Treatment (ST) intervention in helping recently diagnosed cancer patients quit smoking. Both interventions include 4 weekly counseling sessions and FDA-approved smoking cessation medication advice. The IT includes an additional 4 biweekly and 3 monthly booster sessions as well as dispensal of the recommended FDA-approved smoking cessation medication at no cost. The trial is enrolling patients with suspected or newly diagnosed cancer who have smoked a cigarette in the past 30 days. Participants are randomly assigned to receive the ST or IT condition. Tobacco cessation outcomes are assessed at 3 and 6 months. The primary study outcome is 7-day point prevalence biochemically-validated tobacco abstinence. Secondary study outcomes include the incremental cost-effectiveness of the IT vs. ST. Discussion This trial will answer key questions about delivering tobacco treatment interventions to newly diagnosed cancer patients. If found to be efficacious and cost-effective, this treatment will serve as a model to be integrated into oncology care settings nation-wide, as we strive to improve treatment outcomes and quality of life for cancer patients.

show abstract